The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
Zacks.com on MSN4h
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLAThe FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $11.85 which represents a slight increase of $1.71 or 16.86% from the prior close of $10.14. The stock opened at $12.6 and ...
Barclays (LON:BARC) reaffirmed its positive stance on Replimune Group (NASDAQ:REPL), maintaining an Overweight rating and a $17.00 price target, representing significant upside from the current price ...
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary ...
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback